Cariati M, Bennett-Britton T M, Pinder S E, Purushotham A D
Cambridge Breast Unit, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 2QQ, UK.
Surg Oncol. 2005 Nov;14(3):133-43. doi: 10.1016/j.suronc.2005.07.004. Epub 2005 Sep 9.
"Inflammatory" breast cancer is a rare and very aggressive form of the disease characterised by rapid onset and dismal outcome.
This review describes the clinical and molecular aspects of inflammatory breast cancer. The relevant English language literature on of inflammatory breast cancer was searched via Medline and ISI Web of Knowledge Cross Search (1924-2005), cross-referencing with key articles on the subject.
An increasing body of evidence demonstrates that inflammatory breast cancer is a unique form of breast cancer. A prompt diagnosis and multidisciplinary approach (based on neoadjuvant chemotherapy, loco-regional treatment with surgery and/or radiotherapy, followed in some cases by adjuvant systemic therapy) are the two factors most likely to have an impact on survival. As the molecular basis of the disease is becoming increasingly more defined, new potential therapeutic targets may arise in the future.
“炎性”乳腺癌是一种罕见且极具侵袭性的疾病形式，其特点是发病迅速且预后不佳。
本综述描述了炎性乳腺癌的临床和分子方面。通过医学文献数据库（Medline）和科学网（ISI Web of Knowledge Cross Search，1924 - 2005年）检索了关于炎性乳腺癌的相关英文文献，并与该主题的关键文章进行交叉引用。
越来越多的证据表明，炎性乳腺癌是一种独特的乳腺癌形式。及时诊断和多学科方法（基于新辅助化疗、手术和/或放疗的局部区域治疗，某些情况下随后进行辅助全身治疗）是最有可能影响生存的两个因素。随着该疾病的分子基础越来越明确，未来可能会出现新的潜在治疗靶点。
